Association of IFN-γ signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2668-2678

  Respa, Annedore ^a   Bukur, Juergen ^a   Ferrone, Soldano ^c   Pawelec, Graham ^b   Zhao, Yingdong ^d   Wang, Ena ^e   Marincola, Francesco M ^e   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; JANUS KINASE 2;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIGEN PRESENTATION; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; JANUS KINASE 2; MELANOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 79955495231     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2114     Document Type: Article

References (32)

1. Amadori M. The role of IFN-alpha as homeostatic agent in the inflammatory response: a balance between danger and response? J Interferon Cytokine Res 2007;27:181-9.
2. Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007;13:5010-9. (Pubitemid 47502065)
3. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559-68. (Pubitemid 351913674)
4. Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 2008;101:249-76.
5. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002;21:1251-62. (Pubitemid 34185242)
6. Vannucchi S, Chiantore MV, Mangino G, Percario ZA, Affabris E, Fiorucci G, et al. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr Med Chem 2007;14:667-79. (Pubitemid 46477719)
7. Rane SG, Reddy ES. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:56662-79.
8. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
9. Marqués L, Brucet M, Lloberas J, Celada A. STAT1 regulates lipopolysaccharide- and TNF-alpha-dependent expression of transporter associated with antigen p processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J Immunol 2004;173:1103-10. (Pubitemid 38924285)
10. Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter- Fourt I. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 2005;174:3948-58. (Pubitemid 40395969)
11. Rodríguez T, Méndez R, Del Campo A, Aptsiauri N, Martín J, Orozco G, et al. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 2007;59:123-33. (Pubitemid 46130791)
12. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272:28779-85. (Pubitemid 27517837)
13. Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 2000;60:5789-96.
14. Rodríguez T, Méndez R, Del Campo A, Jiménez P, Aptsiauri N, Garrido F, et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 2007;7:34.
15. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005;66:185-94. (Pubitemid 41243306)
16. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, et al. A method to generate antigen-specific mAb capable of staining formalin- fixed, paraffin-embedded tissue sections. J Immunol Methods 2005;299:139-51. (Pubitemid 40725931)
17. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003;62:382-93.
18. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306. (Pubitemid 16020728)
19. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 2008;68:122-31. (Pubitemid 351380113)
20. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994;88:794-802. (Pubitemid 24375795)
21. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Gene transfer of the co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 1999;50:242-9. (Pubitemid 29399896)
22. Simon R. Microarray-based expression profiling and informatics. Curr Opin Biotechnol 2008;19:26-9. (Pubitemid 351226512)
23. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61. (Pubitemid 28293291)
24. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48. (Pubitemid 44631652)
25. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002;21:2504-12. (Pubitemid 34438103)
26. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. Interferon: cellular executioner or white knight? Curr Med Chem 2007;14:1279-89.
27. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 2007;5:1331-41.
28. Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, et al. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 2003;13:219-29. (Pubitemid 36683763)
29. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111:4809-12.
30. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, et al. Defective JAK-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000;85:720-5. (Pubitemid 30080488)
31. Simpson J, Al-Attar A, Watson N, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010;59:926-933.
32. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000;19:2505-10. (Pubitemid 30339206)